Key Takeaways
- Sanofi raised its full-year sales forecast for 2026.
- The company attributed the growth to strong demand for Dupixent, an asthma drug.
- New CEO Belen Garijo has made changes to Sanofi’s executive team and R&D strategy.
Sanofi, a French pharmaceutical giant, has revised its sales forecast for 2026 upwards, citing robust demand for its flagship product Dupixent. The company now expects an increase of 10% in sales at constant exchange rates compared to its previous high-single-digit growth projection.
In her first weeks as CEO, Belen Garijo has implemented several strategic changes aimed at revitalizing Sanofi’s drug development engine. These include overhauling the executive team and appointing a new R&D chief. Additionally, she has abandoned plans for seeking approval of an experimental eczema drug named amlitelimab.
The revised sales outlook comes as investors closely monitor Garijo's leadership to ensure Sanofi maintains its growth trajectory beyond Dupixent’s success. The company’s second-quarter business operating income reached €3.29 billion, significantly surpassing analyst estimates of €2.96 billion. Quarterly revenue also exceeded expectations, hitting €11.60 billion compared to the estimated €10.85 billion.
Garijo's first address as CEO focused on her plans to secure a sustainable growth path for Sanofi. She emphasized the importance of maintaining Dupixent’s market position while exploring new opportunities in drug development. The company continues to expect business operating income to grow slightly faster than sales, indicating confidence in its future financial performance.
Analysts and investors are watching closely as Sanofi navigates this transition period under Garijo's leadership. Her decisions on executive appointments and R&D strategies will be crucial in determining the company’s long-term success beyond Dupixent’s current market dominance.
Sanofi’s revised sales forecast reflects a positive outlook for 2026, driven by continued strong demand for its key product. The company remains committed to maintaining its growth trajectory despite ongoing scrutiny from investors.
